Masitinib (AB1010) CAS 790299-79-5 China supply with best price

Melting point 90-95?C
density 1.280±0.06 g/cm3(Predicted)
storage temp. Refrigerator
pka 13.24±0.70(Predicted)

Categories:

Product Name: Masitinib (AB1010)
Synonyms: AB-1010; AB 1010; AB1010; MASITINIB. BRAND NAME: KINAVET; MASIVET.;Masitinib. Brand name: Kinavet;MASITINIB;4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide;4-((4-Methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide;Ab 1010;Ab1010;Ab-1010
CAS: 790299-79-5
MF: C28H30N6OS
MW: 498.64
EINECS: 226-164-5

Masitinib, also known as methotrexate masitinib, is studied and developed by the AB Science, a platelet-derived growth factor alpha/beta receptor tyrosine kinase inhibitor for the treatment of multiple myeloma, gastrointestinal stromal tumors and prostate cancer.
The drug had respectively, been entitled by FDA for the treatment of pancreatic cancer and ALS orphans disease in 2009 and 2015. On August 8, 2016, it has qualified as EMA orphan drug.
Masitinib is a novel kind of oral administrated tyrosine kinase inhibitors that could be targeted to immunizing important cellular mast cells and macrophages by inhibiting a certain amount of kinase. Based on its unique mechanism of action, masitinib can be developed for application in tumors, inflammatory diseases and certain central nervous system diseases.
In the oncology, due to its immunotherapy effect, Masitinib may affect the survival period of cancer patients (single administration or in combination with chemotherapy). By acting on mast cells and microglia, and further inhibiting the activation of the inflammatory process, Masitinib is effective against certain inflammatory, central nervous system disorders as well as symptoms associated with degeneration of these diseases.